CD274 and non-small cell lung carcinoma: Based on the results of the KEYNOTE-024 study, the FDA approved use of pembrolizumab for newly diagnosed advanced NSCLC patients with a ≥50% PD-L1 expression rate and no clear driver gene mutation.